412 related articles for article (PubMed ID: 28064239)
1. Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma.
Krysiak K; Gomez F; White BS; Matlock M; Miller CA; Trani L; Fronick CC; Fulton RS; Kreisel F; Cashen AF; Carson KR; Berrien-Elliott MM; Bartlett NL; Griffith M; Griffith OL; Fehniger TA
Blood; 2017 Jan; 129(4):473-483. PubMed ID: 28064239
[TBL] [Abstract][Full Text] [Related]
2. Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.
Myklebust JH; Brody J; Kohrt HE; Kolstad A; Czerwinski DK; Wälchli S; Green MR; Trøen G; Liestøl K; Beiske K; Houot R; Delabie J; Alizadeh AA; Irish JM; Levy R
Blood; 2017 Feb; 129(6):759-770. PubMed ID: 28011673
[TBL] [Abstract][Full Text] [Related]
3. Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma.
Li H; Kaminski MS; Li Y; Yildiz M; Ouillette P; Jones S; Fox H; Jacobi K; Saiya-Cork K; Bixby D; Lebovic D; Roulston D; Shedden K; Sabel M; Marentette L; Cimmino V; Chang AE; Malek SN
Blood; 2014 Mar; 123(10):1487-98. PubMed ID: 24435047
[TBL] [Abstract][Full Text] [Related]
4. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma.
Okosun J; Bödör C; Wang J; Araf S; Yang CY; Pan C; Boller S; Cittaro D; Bozek M; Iqbal S; Matthews J; Wrench D; Marzec J; Tawana K; Popov N; O'Riain C; O'Shea D; Carlotti E; Davies A; Lawrie CH; Matolcsy A; Calaminici M; Norton A; Byers RJ; Mein C; Stupka E; Lister TA; Lenz G; Montoto S; Gribben JG; Fan Y; Grosschedl R; Chelala C; Fitzgibbon J
Nat Genet; 2014 Feb; 46(2):176-181. PubMed ID: 24362818
[TBL] [Abstract][Full Text] [Related]
5. Follicular lymphoma-associated mutations in vacuolar ATPase ATP6V1B2 activate autophagic flux and mTOR.
Wang F; Gatica D; Ying ZX; Peterson LF; Kim P; Bernard D; Saiya-Cork K; Wang S; Kaminski MS; Chang AE; Phillips T; Klionsky DJ; Malek SN
J Clin Invest; 2019 Mar; 129(4):1626-1640. PubMed ID: 30720463
[TBL] [Abstract][Full Text] [Related]
6. The mutational landscape of ocular marginal zone lymphoma identifies frequent alterations in TNFAIP3 followed by mutations in TBL1XR1 and CREBBP.
Jung H; Yoo HY; Lee SH; Shin S; Kim SC; Lee S; Joung JG; Nam JY; Ryu D; Yun JW; Choi JK; Ghosh A; Kim KK; Kim SJ; Kim WS; Park WY; Ko YH
Oncotarget; 2017 Mar; 8(10):17038-17049. PubMed ID: 28152507
[TBL] [Abstract][Full Text] [Related]
7. Pan-HDAC Inhibitors Restore PRDM1 Response to IL21 in CREBBP-Mutated Follicular Lymphoma.
Desmots F; Roussel M; Pangault C; Llamas-Gutierrez F; Pastoret C; Guiheneuf E; Le Priol J; Camara-Clayette V; Caron G; Henry C; Belaud-Rotureau MA; Godmer P; Lamy T; Jardin F; Tarte K; Ribrag V; Fest T
Clin Cancer Res; 2019 Jan; 25(2):735-746. PubMed ID: 30348636
[TBL] [Abstract][Full Text] [Related]
8. B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells.
Seda V; Mraz M
Eur J Haematol; 2015 Mar; 94(3):193-205. PubMed ID: 25080849
[TBL] [Abstract][Full Text] [Related]
9. New concepts in follicular lymphoma biology: From BCL2 to epigenetic regulators and non-coding RNAs.
Devan J; Janikova A; Mraz M
Semin Oncol; 2018 Oct; 45(5-6):291-302. PubMed ID: 30360879
[TBL] [Abstract][Full Text] [Related]
10. Inactivating mutations of acetyltransferase genes in B-cell lymphoma.
Pasqualucci L; Dominguez-Sola D; Chiarenza A; Fabbri G; Grunn A; Trifonov V; Kasper LH; Lerach S; Tang H; Ma J; Rossi D; Chadburn A; Murty VV; Mullighan CG; Gaidano G; Rabadan R; Brindle PK; Dalla-Favera R
Nature; 2011 Mar; 471(7337):189-95. PubMed ID: 21390126
[TBL] [Abstract][Full Text] [Related]
11. Pathogenesis of follicular lymphoma.
Lackraj T; Goswami R; Kridel R
Best Pract Res Clin Haematol; 2018 Mar; 31(1):2-14. PubMed ID: 29452662
[TBL] [Abstract][Full Text] [Related]
12. The CREBBP Acetyltransferase Is a Haploinsufficient Tumor Suppressor in B-cell Lymphoma.
Zhang J; Vlasevska S; Wells VA; Nataraj S; Holmes AB; Duval R; Meyer SN; Mo T; Basso K; Brindle PK; Hussein S; Dalla-Favera R; Pasqualucci L
Cancer Discov; 2017 Mar; 7(3):322-337. PubMed ID: 28069569
[TBL] [Abstract][Full Text] [Related]
13. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
Davis RE; Ngo VN; Lenz G; Tolar P; Young RM; Romesser PB; Kohlhammer H; Lamy L; Zhao H; Yang Y; Xu W; Shaffer AL; Wright G; Xiao W; Powell J; Jiang JK; Thomas CJ; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Johnson NA; Rimsza LM; Campo E; Jaffe ES; Wilson WH; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Pierce SK; Staudt LM
Nature; 2010 Jan; 463(7277):88-92. PubMed ID: 20054396
[TBL] [Abstract][Full Text] [Related]
14. Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma.
González-Rincón J; Méndez M; Gómez S; García JF; Martín P; Bellas C; Pedrosa L; Rodríguez-Pinilla SM; Camacho FI; Quero C; Pérez-Callejo D; Rueda A; Llanos M; Gómez-Codina J; Piris MA; Montes-Moreno S; Bárcena C; Rodríguez-Abreu D; Menárguez J; de la Cruz-Merino L; Monsalvo S; Parejo C; Royuela A; Kwee I; Cascione L; Arribas A; Bertoni F; Mollejo M; Provencio M; Sánchez-Beato M
PLoS One; 2019; 14(2):e0212813. PubMed ID: 30802265
[TBL] [Abstract][Full Text] [Related]
15. Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation.
Green MR; Kihira S; Liu CL; Nair RV; Salari R; Gentles AJ; Irish J; Stehr H; Vicente-Dueñas C; Romero-Camarero I; Sanchez-Garcia I; Plevritis SK; Arber DA; Batzoglou S; Levy R; Alizadeh AA
Proc Natl Acad Sci U S A; 2015 Mar; 112(10):E1116-25. PubMed ID: 25713363
[TBL] [Abstract][Full Text] [Related]
16. CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis.
Huang YH; Cai K; Xu PP; Wang L; Huang CX; Fang Y; Cheng S; Sun XJ; Liu F; Huang JY; Ji MM; Zhao WL
Signal Transduct Target Ther; 2021 Jan; 6(1):10. PubMed ID: 33431788
[TBL] [Abstract][Full Text] [Related]
17. DC-SIGN binding to mannosylated B-cell receptors in follicular lymphoma down-modulates receptor signaling capacity.
Valle-Argos B; Chiodin G; Bryant DJ; Taylor J; Lemm E; Duriez PJ; Rock PJ; Strefford JC; Forconi F; Burack RW; Packham G; Stevenson FK
Sci Rep; 2021 Jun; 11(1):11676. PubMed ID: 34083646
[TBL] [Abstract][Full Text] [Related]
18. Follicular lymphoma, a B cell malignancy addicted to epigenetic mutations.
Korfi K; Ali S; Heward JA; Fitzgibbon J
Epigenetics; 2017 May; 12(5):370-377. PubMed ID: 28106467
[TBL] [Abstract][Full Text] [Related]
19. Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial.
Bartlett NL; Costello BA; LaPlant BR; Ansell SM; Kuruvilla JG; Reeder CB; Thye LS; Anderson DM; Krysiak K; Ramirez C; Qi J; Siegel BA; Griffith M; Griffith OL; Gomez F; Fehniger TA
Blood; 2018 Jan; 131(2):182-190. PubMed ID: 29074501
[TBL] [Abstract][Full Text] [Related]
20. Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma.
Ding N; Li X; Shi Y; Ping L; Wu L; Fu K; Feng L; Zheng X; Song Y; Pan Z; Zhu J
Oncotarget; 2015 Jun; 6(17):15122-36. PubMed ID: 25944695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
